{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:31:36Z","timestamp":1787841096264,"version":"build-2784847793"},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1]]},"abstract":"Abstract<\/jats:title>\n \n Purpose:<\/jats:title>\n Tuberculosis (TB) is a chronic disease that negatively impacts the quality of life (QoL) due to the physical, emotional, and social challenges it poses. Digital technology has transformed the management of TB by improving patient outcomes and enabling more efficient and personalized care. One such innovation, video-observed therapy (VOT), enables healthcare workers to observe the patient taking their medication in real-time via video call.<\/jats:p>\n <\/jats:sec>\n \n Aim:<\/jats:title>\n This study aims to compare the impact of VOT and directly observed therapy (DOTs) on QoL in TB patients.<\/jats:p>\n <\/jats:sec>\n \n Methods:<\/jats:title>\n \n This observational and prospective study was conducted at a TB hospital in India, for 6 months on 110 TB patients, with 55 each in VOT group and DOTs group. Ethical approval was obtained, and patients were provided with an information sheet before signing the consent form. Demographic data were collected, and QoL was assessed using SF-36 scale. Statistical analyses were performed using SPSS software, with ANOVA and\n t<\/jats:italic>\n -tests employed to compare variables (\n P<\/jats:italic>\n < 0.05 was considered significant at a 95% confidence level).\n <\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n Patients in the VOT group showed significantly higher QoL scores (44.10 \u00b1 4.60, 59.36 \u00b1 5.56) compared to the DOTs group (34.39 \u00b1 2.88, 48.80 \u00b1 4.05) after completing intensive and continuous phases of treatment, respectively. These improvements were notable when compared to the initiation of treatment scores (17.23 \u00b1 4.27 for VOT and 10.82 \u00b1 4.07 for DOTs), indicating sustained positive outcomes.<\/jats:p>\n <\/jats:sec>\n \n Conclusion:<\/jats:title>\n This study provides robust evidence that integrating VOT into standard TB treatment protocols significantly enhances patients\u2019 QoL and reduces the overall disease burden.<\/jats:p>\n <\/jats:sec>","DOI":"10.4103\/picr.picr_9_25","type":"journal-article","created":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T22:00:07Z","timestamp":1759010407000},"page":"17-22","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Quality of life in tuberculosis patients: A comparative study of video-observed therapy and directly observed therapy"],"prefix":"10.4103","volume":"17","author":[{"given":"Vikas","family":"Chauhan","sequence":"first","affiliation":[{"name":"Department of Pharmaceutics, IIMT College of Pharmacy, Greater Noida, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid Umer","family":"Khayam","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Public Health, District TB Officer, Chest Clinic, NITRD, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonal","family":"Setya","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, SGT College of Pharmacy, SGT University, Gurugram, Haryana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,9,25]]},"reference":[{"key":"R1-20260217","doi-asserted-by":"crossref","first-page":"1234785","DOI":"10.3389\/fimmu.2023.1234785","article-title":"The impact of the COVID-19 pandemic on the global tuberculosis epidemic","volume":"14","author":"Falzon","year":"2023","journal-title":"Front Immunol"},{"key":"R2-20260217","doi-asserted-by":"crossref","first-page":"100121","DOI":"10.1016\/j.jctube.2019.100121","article-title":"Quality of life with tuberculosis","volume":"17","author":"Aggarwal","year":"2019","journal-title":"J Clin Tuberc Other Mycobact Dis"},{"key":"R3-20260217","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1186\/s12913-023-09381-z","article-title":"Survey to measure the quality of life of patients with tuberculosis in Alexandria, Egypt: A cross-sectional study","volume":"23","author":"Hammouda","year":"2023","journal-title":"BMC Health Serv Res"},{"key":"R4-20260217","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ejca.2019.08.016","article-title":"Current state of quality of life and patient-reported outcomes research","volume":"121","author":"Bottomley","year":"2019","journal-title":"Eur J Cancer"},{"key":"R5-20260217","doi-asserted-by":"crossref","first-page":"e199","DOI":"10.1016\/S1473-3099(18)30111-7","article-title":"Tuberculosis: Advances and challenges in development of new diagnostics and biomarkers","volume":"18","author":"Walzl","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"R6-20260217","doi-asserted-by":"crossref","first-page":"82","DOI":"10.4046\/trd.2022.0148","article-title":"Improving tuberculosis medication adherence:The potential of integrating digital technology and health belief model","volume":"86","author":"Sazali","year":"2023","journal-title":"Tuberc Respir Dis (Seoul)"},{"key":"R7-20260217","doi-asserted-by":"crossref","first-page":"2000493","DOI":"10.1183\/13993003.00493-2020","article-title":"Video-observed therapy and medication adherence for tuberculosis patients:randomised controlled trial in Moldova","volume":"56","author":"Ravenscroft","year":"2020","journal-title":"Eur Respir J"},{"key":"R8-20260217","doi-asserted-by":"crossref","first-page":"100248","DOI":"10.1016\/j.jctube.2021.100248","article-title":"Facility-based directly observed therapy (DOT) for tuberculosis during COVID-19: A community perspective","volume":"24","author":"Zimmer","year":"2021","journal-title":"J Clin Tuberc Other Mycobact Dis"},{"key":"R9-20260217","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.amepre.2021.10.013","article-title":"Video-observed therapy versus directly observed therapy in patients with tuberculosis","volume":"62","author":"Truong","year":"2022","journal-title":"Am J Prev Med"},{"key":"R11-20260217","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0167-6296(01)00130-8","article-title":"The estimation of a preference-based measure of health from the SF-36","volume":"21","author":"Brazier","year":"2002","journal-title":"J Health Econ"},{"key":"R12-20260217","first-page":"135","article-title":"Assessment of quality of life in tuberculosis affected individuals on DOTS: A longitudinal follow-up study in South Delhi","volume":"45","author":"Pritam","year":"2013","journal-title":"J Commun Dis"},{"key":"R13-20260217","doi-asserted-by":"crossref","first-page":"45","DOI":"10.4236\/jtr.2019.72005","article-title":"Deciphering the quality of life among tuberculosis patients under RNTCP in Karnataka, India","volume":"7","author":"Iti","year":"2019","journal-title":"J Tuberc Res"},{"key":"R14-20260217","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.4103\/jfmpc.jfmpc_347_18","article-title":"Effect of DOTS on quality of life among tuberculosis patients: A follow-up study in a health district of Kolkata","volume":"8","author":"Banerjee","year":"2019","journal-title":"J Family Med Prim Care"},{"key":"R15-20260217","first-page":"729","article-title":"The diagnosis and treatment of tuberculosis","volume":"116","author":"Su\u00e1rez","year":"2019","journal-title":"Dtsch Arztebl Int"},{"key":"R16-20260217","doi-asserted-by":"crossref","first-page":"152","DOI":"10.12688\/wellcomeopenres.17865.1","article-title":"Acceptability of video observed treatment vs. directly observed treatment for tuberculosis: a comparative analysis between south and central India","volume":"7","author":"Rao","year":"2022","journal-title":"Wellcome Open Res"},{"key":"R17-20260217","article-title":"The impact of digital adherence technologies on health outcomes in tuberculosis:a systematic review and meta-analysis","author":"Mohamed","year":"2024","journal-title":"medRxiv."}],"container-title":["Perspectives in Clinical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/picr.picr_9_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:42:16Z","timestamp":1787838136000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/picr.picr_9_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,25]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/picr.picr_9_25","relation":{},"ISSN":["2229-3485","2229-5488"],"issn-type":[{"value":"2229-3485","type":"print"},{"value":"2229-5488","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,25]]},"assertion":[{"value":"2025-01-12","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-30","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}